Ling Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ling Li has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Nadzim. Ramli
Quantitative Biosciences, MSD, Singapore, Singapore
27 shared publications - Andrey Loboda
Merck & Co., Inc. 7 Boston, MA
17 shared publications - Casey J. Moure
Department of Pathology, Duke University, Durham, North Carolina
17 shared publications - Chunsheng Zhang
Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts
17 shared publications - Corinne E. Gustafson
The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts
17 shared publications - Derek Y. Chiang
Novartis Institutes for Biomedical Research, Cambridge, MA, USA
17 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S2 shows the deletion of AEBP1 in human CAF subclusters. (A) UMAP showing the subtypes identified in the dataset. (B) Expression (in scTransform values) of AEBP1 across subtypes in non-transfected and AEBP1-perturbed cells. (C) Plasmid map of pRDA_208 that was used to generate AEBP1 KO human CAFs.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S2 shows the deletion of AEBP1 in human CAF subclusters. (A) UMAP showing the subtypes identified in the dataset. (B) Expression (in scTransform values) of AEBP1 across subtypes in non-transfected and AEBP1-perturbed cells. (C) Plasmid map of pRDA_208 that was used to generate AEBP1 KO human CAFs.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary table S2 shows the sequences of sgRNAs and primers used in various experiments
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary table S2 shows the sequences of sgRNAs and primers used in various experiments
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S6 shows the immunophenotyping of MC38 tumors co-injected with AEBP1 wild-type (WT) or knockout (KO) NIH3T3 fibroblasts (A-C) Overall population composition and phenotypes of tumor-infiltrating lymphocytes (A) and FACS gating strategy of Myeloid panel (B) and T-cell panel (C) of co-implanted MC38 tumors with AEBP1 WT fibroblasts or AEBP1.KO fibroblasts that were either treated with anti-PD-1 or isotype control. (D) Upregulated and downregulated genes obtained from molecular profiling of MC38 tumors co-implanted with AEBP1.KO fibroblasts (red circle) and AEBP1 WT fibroblasts (blue circle). (E) Mean tumor growth curves and (F) individual tumor growth curves from anti-PD-1 responders that were rechallenged with MC38 tumors. Naïve mice were used as a control group. N = 5 per group.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S6 shows the immunophenotyping of MC38 tumors co-injected with AEBP1 wild-type (WT) or knockout (KO) NIH3T3 fibroblasts (A-C) Overall population composition and phenotypes of tumor-infiltrating lymphocytes (A) and FACS gating strategy of Myeloid panel (B) and T-cell panel (C) of co-implanted MC38 tumors with AEBP1 WT fibroblasts or AEBP1.KO fibroblasts that were either treated with anti-PD-1 or isotype control. (D) Upregulated and downregulated genes obtained from molecular profiling of MC38 tumors co-implanted with AEBP1.KO fibroblasts (red circle) and AEBP1 WT fibroblasts (blue circle). (E) Mean tumor growth curves and (F) individual tumor growth curves from anti-PD-1 responders that were rechallenged with MC38 tumors. Naïve mice were used as a control group. N = 5 per group.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S3 shows the generation of AEBP1 knockout mouse fibrablasts. (A) Expression levels of long and short isoform transcripts of AEBP1 in NIH3T3 wild-type (WT) fibroblasts.(B) Sanger sequencing results confirming homozygous AEBP1 knockout (KO) clones derived from NIH3T3 mouse fibroblasts.(C) RT-PCR validation of three NIH3T3 AEBP1.KO clones: F5, G5, and H7.(D) CTG cell proliferation assay comparing monocultures of NIH3T3 WT fibroblasts and AEBP1.KO clones F5, G5, and H7 (N = 5 technical replicates). Percentage cell viability was normalized to luminescence data from WT fibroblasts.(E) Venn diagram illustrating significantly down-regulated genes in AEBP1.KO clones F5, G5, and H7 relative to WT cells. Significance thresholds: log2(fold change) < -0.75 and adjusted p-value <0.001.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S3 shows the generation of AEBP1 knockout mouse fibrablasts. (A) Expression levels of long and short isoform transcripts of AEBP1 in NIH3T3 wild-type (WT) fibroblasts.(B) Sanger sequencing results confirming homozygous AEBP1 knockout (KO) clones derived from NIH3T3 mouse fibroblasts.(C) RT-PCR validation of three NIH3T3 AEBP1.KO clones: F5, G5, and H7.(D) CTG cell proliferation assay comparing monocultures of NIH3T3 WT fibroblasts and AEBP1.KO clones F5, G5, and H7 (N = 5 technical replicates). Percentage cell viability was normalized to luminescence data from WT fibroblasts.(E) Venn diagram illustrating significantly down-regulated genes in AEBP1.KO clones F5, G5, and H7 relative to WT cells. Significance thresholds: log2(fold change) < -0.75 and adjusted p-value <0.001.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Cancer-associated fibroblasts (CAF) are key components of the tumor microenvironment (TME) that promote tumor progression either directly through tumor–CAF interactions or indirectly by influencing tumor-infiltrating immune cells, thereby creating an immunosuppressive TME. High stromal signatures have been associated with reduced therapeutic efficacy and resistance to immune checkpoint blockades. Adipocyte enhancer–binding protein 1 (AEBP1) is predominantly expressed in myofibroblasts, and its expression is further increased in CAFs that produce the extracellular matrix. It has two isoforms: The extracellular isoform binds to collagen and promotes collagen remodeling, whereas the intracellular isoform modulates transcription and signaling. We observed the expression of both isoforms in primary human CAFs. Our data showed that the combined knockout (KO) of both AEBP1 isoforms via gene editing decreased CAF proliferation, collagen gel contractility, and CAF-mediated tumor cell proliferation in vitro. AEBP1 KO mouse fibroblasts demonstrated reduced activity in both in vitro assays and in vivo within a coimplantation mouse model. RNA sequencing revealed that AEBP1 KO downregulated the collagen biosynthesis and extracellular matrix organization–related pathways in mouse fibroblasts and human CAFs. Importantly, AEBP1 loss in fibroblasts led to significant alterations in tumor cell phenotypes, including a marked reduction of tumor cells exhibiting an epithelial–mesenchymal transition signature in vivo. Furthermore, AEBP1 KO in CAFs enhanced the anti-PD-1–induced effector T-cell function and the anti–PD-1 efficacy. Our findings indicate that AEBP1 plays a crucial role in regulating the function of CAFs within the TME. Targeting AEBP1 could be a promising strategy to inhibit the tumor-promoting activities of CAFs and to overcome resistance to anti–PD-1 immunotherapy.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Cancer-associated fibroblasts (CAF) are key components of the tumor microenvironment (TME) that promote tumor progression either directly through tumor–CAF interactions or indirectly by influencing tumor-infiltrating immune cells, thereby creating an immunosuppressive TME. High stromal signatures have been associated with reduced therapeutic efficacy and resistance to immune checkpoint blockades. Adipocyte enhancer–binding protein 1 (AEBP1) is predominantly expressed in myofibroblasts, and its expression is further increased in CAFs that produce the extracellular matrix. It has two isoforms: The extracellular isoform binds to collagen and promotes collagen remodeling, whereas the intracellular isoform modulates transcription and signaling. We observed the expression of both isoforms in primary human CAFs. Our data showed that the combined knockout (KO) of both AEBP1 isoforms via gene editing decreased CAF proliferation, collagen gel contractility, and CAF-mediated tumor cell proliferation in vitro. AEBP1 KO mouse fibroblasts demonstrated reduced activity in both in vitro assays and in vivo within a coimplantation mouse model. RNA sequencing revealed that AEBP1 KO downregulated the collagen biosynthesis and extracellular matrix organization–related pathways in mouse fibroblasts and human CAFs. Importantly, AEBP1 loss in fibroblasts led to significant alterations in tumor cell phenotypes, including a marked reduction of tumor cells exhibiting an epithelial–mesenchymal transition signature in vivo. Furthermore, AEBP1 KO in CAFs enhanced the anti-PD-1–induced effector T-cell function and the anti–PD-1 efficacy. Our findings indicate that AEBP1 plays a crucial role in regulating the function of CAFs within the TME. Targeting AEBP1 could be a promising strategy to inhibit the tumor-promoting activities of CAFs and to overcome resistance to anti–PD-1 immunotherapy.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S1 shows the specificity of the custom designed isoform specific primer pairs in HEK293 cells overexpressing either the long (ACLP) or short (iAEBP1) isoforms of AEBP1 by RT-PCR.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S1 shows the specificity of the custom designed isoform specific primer pairs in HEK293 cells overexpressing either the long (ACLP) or short (iAEBP1) isoforms of AEBP1 by RT-PCR.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S5 shows the scRNA-Seq analysis of MC38 tumor cells isolated from co-injection model (A) Tumor volumes on the day of tumor harvest for single cell RNA-seq. (B) 2D UMAP of integrated single cell RNA-seq data of all tumor samples. Tumor cells, immune cells and CAF clusters were identified and labeled by marker gene expression. The MC38 tumor cluster of interest is marked by a circle. (C) 2D UMAP of sub-clustering of single cell RNA-seq of the MC38 tumor cluster. (D) Scaled expression of top cluster identifying genes from each tumor sub-cluster. (E-H) Top 15 enriched pathways of top 100 cluster identifying genes for tumor sub-cluster 0, 1, 3, and 4. The significance of enrichment is identified by hypergeometric tests against MsigDB pathway gene sets. Significant (adjusted p-value <0.05) pathways are labeled in red.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S5 shows the scRNA-Seq analysis of MC38 tumor cells isolated from co-injection model (A) Tumor volumes on the day of tumor harvest for single cell RNA-seq. (B) 2D UMAP of integrated single cell RNA-seq data of all tumor samples. Tumor cells, immune cells and CAF clusters were identified and labeled by marker gene expression. The MC38 tumor cluster of interest is marked by a circle. (C) 2D UMAP of sub-clustering of single cell RNA-seq of the MC38 tumor cluster. (D) Scaled expression of top cluster identifying genes from each tumor sub-cluster. (E-H) Top 15 enriched pathways of top 100 cluster identifying genes for tumor sub-cluster 0, 1, 3, and 4. The significance of enrichment is identified by hypergeometric tests against MsigDB pathway gene sets. Significant (adjusted p-value <0.05) pathways are labeled in red.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S4 shows the Tumor infiltrating immune cell profiling in MC38 co-implantation model (A) Schematic of the in vivo co-implantation and FACS study design with or without AEBP1 co-implantation. (B) Mean tumor volumes measured at time of sample collection for FACS. (C) FACS gating strategy for assessment of TILs (D) Quantification of immune infiltrates in MC38 tumor alone and MC38 tumors co-implanted with AEBP1 WT fibroblasts or AEBP1 KO fibroblasts.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary figure S4 shows the Tumor infiltrating immune cell profiling in MC38 co-implantation model (A) Schematic of the in vivo co-implantation and FACS study design with or without AEBP1 co-implantation. (B) Mean tumor volumes measured at time of sample collection for FACS. (C) FACS gating strategy for assessment of TILs (D) Quantification of immune infiltrates in MC38 tumor alone and MC38 tumors co-implanted with AEBP1 WT fibroblasts or AEBP1 KO fibroblasts.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary table S1 shows the flow cytometry panels
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Supplementary table S1 shows the flow cytometry panels
- 29 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 295-309
Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Cancer-associated fibroblasts (CAF) are key components of the tumor microenvironment (TME) that promote tumor progression either directly through tumor–CAF interactions or indirectly by influencing tumor-infiltrating immune cells, thereby creating an immunosuppressive TME. High stromal signatures have been associated with reduced therapeutic efficacy and resistance to immune checkpoint blockades. Adipocyte enhancer–binding protein 1 (AEBP1) is predominantly expressed in myofibroblasts, and its expression is further increased in CAFs that produce the extracellular matrix. It has two isoforms: The extracellular isoform binds to collagen and promotes collagen remodeling, whereas the intracellular isoform modulates transcription and signaling. We observed the expression of both isoforms in primary human CAFs. Our data showed that the combined knockout (KO) of both AEBP1 isoforms via gene editing decreased CAF proliferation, collagen gel contractility, and CAF-mediated tumor cell proliferation in vitro. AEBP1 KO mouse fibroblasts demonstrated reduced activity in both in vitro assays and in vivo within a coimplantation mouse model. RNA sequencing revealed that AEBP1 KO downregulated the collagen biosynthesis and extracellular matrix organization–related pathways in mouse fibroblasts and human CAFs. Importantly, AEBP1 loss in fibroblasts led to significant alterations in tumor cell phenotypes, including a marked reduction of tumor cells exhibiting an epithelial–mesenchymal transition signature in vivo. Furthermore, AEBP1 KO in CAFs enhanced the anti-PD-1–induced effector T-cell function and the anti–PD-1 efficacy. Our findings indicate that AEBP1 plays a crucial role in regulating the function of CAFs within the TME. Targeting AEBP1 could be a promising strategy to inhibit the tumor-promoting activities of CAFs and to overcome resistance to anti–PD-1 immunotherapy.
- 29 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 295-309
Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1
Cancer-associated fibroblasts (CAF) are key components of the tumor microenvironment (TME) that promote tumor progression either directly through tumor–CAF interactions or indirectly by influencing tumor-infiltrating immune cells, thereby creating an immunosuppressive TME. High stromal signatures have been associated with reduced therapeutic efficacy and resistance to immune checkpoint blockades. Adipocyte enhancer–binding protein 1 (AEBP1) is predominantly expressed in myofibroblasts, and its expression is further increased in CAFs that produce the extracellular matrix. It has two isoforms: The extracellular isoform binds to collagen and promotes collagen remodeling, whereas the intracellular isoform modulates transcription and signaling. We observed the expression of both isoforms in primary human CAFs. Our data showed that the combined knockout (KO) of both AEBP1 isoforms via gene editing decreased CAF proliferation, collagen gel contractility, and CAF-mediated tumor cell proliferation in vitro. AEBP1 KO mouse fibroblasts demonstrated reduced activity in both in vitro assays and in vivo within a coimplantation mouse model. RNA sequencing revealed that AEBP1 KO downregulated the collagen biosynthesis and extracellular matrix organization–related pathways in mouse fibroblasts and human CAFs. Importantly, AEBP1 loss in fibroblasts led to significant alterations in tumor cell phenotypes, including a marked reduction of tumor cells exhibiting an epithelial–mesenchymal transition signature in vivo. Furthermore, AEBP1 KO in CAFs enhanced the anti-PD-1–induced effector T-cell function and the anti–PD-1 efficacy. Our findings indicate that AEBP1 plays a crucial role in regulating the function of CAFs within the TME. Targeting AEBP1 could be a promising strategy to inhibit the tumor-promoting activities of CAFs and to overcome resistance to anti–PD-1 immunotherapy.